Your browser doesn't support javascript.
loading
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy.
Bose, Prithviraj; Kuykendall, Andrew T; Miller, Carole; Kurtin, Sandra; Farina, Kyle; Harting, Donald M; Mascarenhas, John O; Mesa, Ruben A.
Afiliación
  • Bose P; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kuykendall AT; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
  • Miller C; Ascension Saint Agnes Hospital Cancer Institute, Ascension Medical Center, Baltimore, USA.
  • Kurtin S; Department of Medicine, University of Arizona Cancer Center, Tucson, USA.
  • Farina K; The Mount Sinai Hospital, Department of Pharmacy, New York, USA.
  • Harting DM; Harting Communications, LLC, Downingtown, PA, USA.
  • Mascarenhas JO; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Mesa RA; Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, North Carolina, USA.
Expert Opin Pharmacother ; 24(9): 1091-1100, 2023 Jun.
Article en En | MEDLINE | ID: mdl-37163478
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Janus Quinasa 2 / Mielofibrosis Primaria Límite: Humans Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Janus Quinasa 2 / Mielofibrosis Primaria Límite: Humans Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos